Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Pulmonology · Alpha-1 Antitrypsin Deficiency

Building Your Care Team and Long-Term Monitoring

At a Glance

Managing Alpha-1 Antitrypsin Deficiency requires a multidisciplinary care team, including a pulmonologist, hepatologist, and genetic counselor. Regular long-term monitoring of lung and liver health, along with family screening, is essential to catch changes early and protect your future.

Managing Alpha-1 Antitrypsin Deficiency (AATD) is a lifelong commitment that is best handled by a specialized team [1][2]. Because AATD can affect multiple parts of the body and carries genetic implications for your family, your care should be “multidisciplinary”—meaning it involves several different types of experts working together [1][3].

Building Your Care Team

Ideally, your care should be coordinated through a specialized Alpha-1 “reference center” or a doctor who has deep experience with the condition [1][4]. Your team should include:

  • Pulmonologist: This specialist manages your lung health, monitors your breathing tests, and determines if you need augmentation therapy [5][6].
  • Hepatologist: Even if you don’t have liver symptoms, a liver specialist is crucial for monitoring potential protein clumping and scarring (fibrosis) [6][7].
  • Genetic Counselor: These professionals help you understand your lab results and guide you through the process of talking to your family members about their own risks [8][1].
  • Primary Care Physician (PCP): Your PCP remains the “hub” for your overall health, ensuring you stay up-to-date on vaccinations (like flu and pneumonia shots) that are vital for protecting your lungs [9].

Your Roadmap for Long-Term Monitoring

AATD is often a slow-moving condition, and regular check-ups allow your team to catch changes early [10][11].

Lung Monitoring

  • Spirometry and DLCO: These are breathing tests performed at least once a year to measure how much air you can hold and how well your lungs transfer oxygen to your blood [12][13].
  • CT Densitometry: Specialized “low-dose” CT scans are the most sensitive way to track the actual loss of lung tissue (emphysema) over time [14][10].

Liver Monitoring

  • Liver Enzymes: Regular blood tests check for signs of liver inflammation [15][16].
  • FibroScan (Elastography): This non-invasive ultrasound-like test measures the “stiffness” of your liver, which helps detect scarring (fibrosis) before it becomes severe [15][17].

Family Screening: The “Cascade” Effect

Because AATD is a genetic condition, your diagnosis is a vital piece of information for your relatives [9][8].

  • Who should be tested? Guidelines strongly recommend testing all “first-degree” relatives—this includes your parents, siblings, and children [9][18].
  • Why test? Early diagnosis in family members allows them to make healthy lifestyle choices (like never starting smoking) and begin monitoring before damage occurs [8][19].

The Psychological Impact and Finding Support

Living with a chronic condition that requires constant monitoring can be emotionally heavy [3]. It is common to experience:

  • “Scanxiety”: Stress or anxiety leading up to your annual breathing tests or scans [8].
  • Perceived Stigma: Feeling judged for respiratory symptoms, especially if you have a history of smoking [20].
  • Patient Advocacy Organizations: Dedicated organizations, such as the Alpha-1 Foundation, are incredible resources for finding local support groups, identifying specialized Alpha-1 reference centers, and staying informed about new research and clinical trials [1].
  • The Power of Support: Research shows that patients with strong social support—from family, friends, or Alpha-1 support groups—report higher life satisfaction and lower stress levels [20][21]. Don’t hesitate to seek out mental health support as a standard part of your care [3].

Common questions in this guide

Which doctors should be on my AATD care team?
Your core team should ideally include a pulmonologist for lung health, a hepatologist for liver monitoring, a genetic counselor, and a primary care physician to coordinate overall care and vaccinations.
How often do I need my lungs checked if I have Alpha-1?
You should have breathing tests, such as spirometry and DLCO, at least once a year. Your doctor may also recommend specialized low-dose CT scans to track any loss of lung tissue over time.
Do I need to see a liver doctor if I don't have liver symptoms?
Yes, consulting a hepatologist is crucial even without symptoms. They can perform regular blood tests and a non-invasive FibroScan to detect early signs of liver inflammation or scarring before it becomes severe.
Which family members should be tested for Alpha-1?
Guidelines strongly recommend testing all first-degree relatives. This includes your parents, siblings, and children, so they can make informed health choices and begin monitoring early if necessary.
Where can I find support for the emotional impacts of AATD?
Patient advocacy organizations like the Alpha-1 Foundation can connect you with local support groups and specialized reference centers. Seeking mental health support is a standard and highly recommended part of managing the stress of chronic monitoring.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many other patients with Alpha-1 do you currently treat in your practice?
  2. 2.Will you be coordinating my care with a hepatologist and a genetic counselor?
  3. 3.Which specific lung function tests (like DLCO or spirometry) will we use to track my progression, and how often?
  4. 4.When should we schedule my first 'baseline' FibroScan or liver ultrasound?
  5. 5.Can you provide a letter or resources to help me explain the importance of genetic testing to my siblings and children?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

When Should Children of Alpha-1 Patients Be Tested?

References

References (21)
  1. 1

    Alpha-1 Antitrypsin Deficiency: Principles of Care.

    Rodrigues JF, Mineiro A, Reis A, et al.

    Acta medica portuguesa 2020; (33(6)):433-439 doi:10.20344/amp.12950.

    PMID: 32504520
  2. 2

    Recent advances in understanding and treating COPD related to α1-antitrypsin deficiency.

    Henao MP, Craig TJ

    Expert review of respiratory medicine 2016; (10(12)):1281-1294 doi:10.1080/17476348.2016.1249851.

    PMID: 27771979
  3. 3

    Anxiety and depression in patients with alpha-1 antitrypsin deficiency: current insights and impact on quality of life.

    Beiko T, Strange C

    Therapeutics and clinical risk management 2019; (15()):959-964 doi:10.2147/TCRM.S175369.

    PMID: 31534340
  4. 4

    The Importance of Reference Centers and Registries for Rare Diseases: The Example of Alpha-1 Antitrypsin Deficiency.

    Miravitlles M, Nuñez A, Torres-Durán M, et al.

    COPD 2020; (17(4)):346-354 doi:10.1080/15412555.2020.1795824.

    PMID: 32791925
  5. 5

    Intravenous Alpha-1 Antitrypsin Therapy for Alpha-1 Antitrypsin Deficiency: The Current State of the Evidence.

    Brantly ML, Lascano JE, Shahmohammadi A

    Chronic obstructive pulmonary diseases (Miami, Fla.) 2018; (6(1)):100-114 doi:10.15326/jcopdf.6.1.2017.0185.

    PMID: 30775428
  6. 6

    Future Perspectives in the Diagnosis and Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency.

    Abreu N, Pereira VM, Pestana M, Jasmins L

    GE Portuguese journal of gastroenterology 2023; (30(5)):327-335 doi:10.1159/000528809.

    PMID: 37868641
  7. 7

    Surgery for patients with Alpha 1 Antitrypsin Deficiency: A review.

    Zamora M

    American journal of surgery 2019; (218(3)):639-647 doi:10.1016/j.amjsurg.2018.10.019.

    PMID: 30360894
  8. 8

    Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency.

    Foil KE

    Therapeutic advances in chronic disease 2021; (12_suppl()):20406223211015954 doi:10.1177/20406223211015954.

    PMID: 34408833
  9. 9

    The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.

    Sandhaus RA, Turino G, Brantly ML, et al.

    Chronic obstructive pulmonary diseases (Miami, Fla.) 2016; (3(3)):668-682 doi:10.15326/jcopdf.3.3.2015.0182.

    PMID: 28848891
  10. 10

    Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.

    Rahaghi FF, Miravitlles M

    Respiratory research 2017; (18(1)):105 doi:10.1186/s12931-017-0574-1.

    PMID: 28558837
  11. 11

    The Role of Computed Tomography for the Evaluation of Lung Disease in Alpha-1 Antitrypsin Deficiency.

    Campos MA, Diaz AA

    Chest 2018; (153(5)):1240-1248 doi:10.1016/j.chest.2017.11.017.

    PMID: 29175361
  12. 12

    Predicting Exacerbations in Alpha-1 Antitrypsin Deficiency Using Clinical and Pulmonary Function Tests: Portuguese EARCO Registry.

    Faria N, Gomes J, Guimarães C, et al.

    Respiration; international review of thoracic diseases 2024; (103(6)):317-325 doi:10.1159/000537759.

    PMID: 38531325
  13. 13

    Progression and Augmentation Therapy in PiSZ and PiZZ Alpha-1 Antitrypsin Deficiency: A Longitudinal Functional and Densitometric Study.

    Esmaili S, Rodríguez Hermosa JL, Vargas Centanaro G, et al.

    Biomolecules 2025; (15(4)) doi:10.3390/biom15040599.

    PMID: 40305326
  14. 14

    Randomized, Placebo-Controlled Trials in Alpha-1 Antitrypsin Deficiency.

    Sandhaus RA

    Annals of the American Thoracic Society 2016; (13 Suppl 4()):S370-3 doi:10.1513/AnnalsATS.201510-684KV.

    PMID: 27564674
  15. 15

    Multi-Society Expert Panel Consensus Guidance Regarding Clinical Assessment and Clinical Trial Endpoints in Adults With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease.

    Loomba R, Clark VC, Mandorfer M, et al.

    Gastroenterology 2025; doi:10.1053/j.gastro.2025.12.012.

    PMID: 41390004
  16. 16

    Liver Involvement in Children with Alpha-1 Antitrypsin Deficiency: A Multicenter Study.

    Cakir M, Sag E, Islek A, et al.

    Pediatric gastroenterology, hepatology & nutrition 2020; (23(2)):146-153 doi:10.5223/pghn.2020.23.2.146.

    PMID: 32206627
  17. 17

    Association of circulating Z-polymer with adverse clinical outcomes and liver fibrosis in adults with alpha-1 antitrypsin deficiency.

    Fromme M, Rademacher L, Amzou S, et al.

    United European gastroenterology journal 2024; (12(8)):1091-1101 doi:10.1002/ueg2.12629.

    PMID: 39024029
  18. 18

    The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency: The Association Between Diagnostic Delay and Worsened Clinical Status.

    Tejwani V, Nowacki AS, Fye E, et al.

    Respiratory care 2019; (64(8)):915-922 doi:10.4187/respcare.06555.

    PMID: 30914495
  19. 19

    Detection of alpha-1 antitrypsin deficiency: the past, present and future.

    Brantly M, Campos M, Davis AM, et al.

    Orphanet journal of rare diseases 2020; (15(1)):96 doi:10.1186/s13023-020-01352-5.

    PMID: 32306990
  20. 20

    A Stress Buffering Perspective on the Progression of Alpha-1 Antitrypsin Deficiency.

    Tian X, Solomon DH, Smith RA

    Health communication 2020; (35(6)):747-755 doi:10.1080/10410236.2019.1584782.

    PMID: 30843437
  21. 21

    Limitations and Challenges of Conducting Budget Impact Analyses in Rare Diseases: A Case Study of Alpha-1 Antitrypsin Deficiency.

    Rueda JD, Sieluk J, Sandhaus RA, Mullins CD

    Value in health regional issues 2020; (23()):70-76 doi:10.1016/j.vhri.2020.04.003.

    PMID: 32892111

This page is for informational purposes only and does not replace professional medical advice. Always consult your Alpha-1 specialist or healthcare provider about your specific care team and monitoring schedule.

Get notified when new evidence is published on Alpha-1-antitrypsin deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.